A Multicenter, Prospective Study of Diarrhea Tolerance of Pyrotinib Combined With Trastumab and Taxane in the First-line Treatment of HER2-positive Advanced Breast Cancer

NCT06362096 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

72

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Trastuzumab+pyrotinib+taxene

Sponsor

Huihua Xiong